Motor neuron disease drug repurposing programme
Lancet Commission report identifies two new modifiable dementia risk factors
The new risk factors identified are untreated vision loss and high low-density lipoprotein
Eli Lilly’s Alzheimer’s drug unanimously endorsed by FDA panel of experts
The company is seeking approval of donanemab to treat patients with early stages of the disease
LifeArc and King’s College London partner to accelerate treatment for motor neurone disease
The rare neurodegenerative disease affects one in every 300 people in the UK
Sanofi presents promising results for investigational frexalimab in relapsing forms of MS
Approximately 85% of patients are initially diagnosed with relapsing forms of the neurological disease
Study suggests hearing aids could prevent onset and progression of dementia
People with severe hearing loss had an increased risk of up to 20% of developing dementia
LifeArc launches £5m motor neurone disease drug repurposing programme
Research teams will be eligible to receive up to £750,000 per project through the programme
New UK research institute launched for motor neurone disease
The research institute will bring together MND labs, clinical centres and researchers
New blood test could one day be used to diagnose Parkinson’s disease
The discovery could potentially lead to the development of a definitive diagnostic test
LSTM and LifeArc announce partnership and research fund to tackle infectious diseases
The research responds to a need for new treatments and diagnostic technologies
LifeArc launches rare disease programme with £100m investment
An initial £40m will go towards the creation of up to five rare disease research centres
LifeArc partners with UK Dementia Research Institute
Dementia affects around 900,000 people in the UK and this is expected to rise to around 1.6 million by 2040
LifeArc creates £10m COVID-19 research fund
Medical research charity joins efforts against coronavirus